Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

The Lancet Gastroenterology & Hepatology · Published 2026-07-16 · DOI 10.1016/s2468-1253(26)00123-8

Free full text

Authors (10)

Rohit Loomba, Jacob George, Laurent Castera, Sven Francque, Eric Lawitz, Ahsan Shoeb, Jesper Ole Clausen, Birgitte Andersen, Anna Bille Larsen, Lise Lotte Gluud

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Loomba, R., George, J., Castera, L., et al. (2026). Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(26)00123-8

Related articles